All abstracts must be submitted on-line through the abstract submission system. Abstracts that are sent via e-mail or fax will not be included in the abstract assessment process.

• All submissions must be completed online by 6 May 2024 by 23:59 CEST (Central European Summer Time, GMT+2).
• All abstracts will initially be reviewed, and will either be accepted or rejected by the Organising Committee. The Organising Committee reserves the right to determine whether an abstract submission is accepted as an oral or a poster presentation.
• The presenting author will be required to register for the conference in order to confirm acceptance of the abstract.
• ESCV reserves the right to exclude any abstract from the scientific programme that is not followed by a participant registration.
• Withdrawal of abstracts is only accepted if notified in writing and subsequently confirmed by the ESCV 2024 Conference Organising Secretariat.
• Accepted abstracts will be published in the conference abstract e-book on the conference website. By submitting an abstract, the authors consent in giving ESCV 2024 permission to publish their abstracts.
• Only studies based on new and not-previously published results can be submitted.

Preparation of Abstracts

• Use only generic drug names.
• Brand, product or company names must not be used in the abstract title or text.
• ESCV reserves the right to replace any brand name with a generic name.
• All abstracts must be submitted in English. 
• An abstract must have a short, specific title (containing no abbreviations) that indicates the nature of the investigation.
• Describe briefly the objectives of the study unless they are contained in the title. Include a brief statement of methods if pertinent. State findings in sufficient detail to support conclusions. Abstracts should not describe research in which the chemical identity or source of the reagent is proprietary or cannot be revealed.
• Standard abbreviations may be used without definition. Non standard abbreviations (kept to a minimum) must be placed in parentheses after the first use of the word or phrase abbreviated.
• Do not include the names or personal information of any patient participating in a study or trial.
• Phrases such as “results will be discussed” or “data will be presented” cannot be accepted.
• The title of abstracts should be a maximum 150 characters.
• The body of the abstract must not exceed 250 words.
• Graphic files and images will not be accepted.
• A maximum of five literature references may be added at the end of the abstract text. For each reference, you can only state the three first author’s names, titel of the paper and bibliography (e.g. Douam F, Hrebikova G, Albrecht YE et al. Single-cell tracking of flavivirus RNA uncovers species-specific interactions with the immune system dictating disease outcome. Nat Commun 2017;8:14781.).
• Please mention all sources of funding of the work described and other acknowledgements briefly at the end of the abstract text. References and acknowledgements are included in the 250-word count for the abstract text.
• The abstract should include the following:

Aim: Clearly state the purpose of the abstract.
Methods: Describe your selection of observations or experimental subjects clearly.
Results: Present your results in a logical sequence in text, table and illustrations.
Conclusions: Emphasize new and important aspects of the study (perhaps as a discussion section) and the conclusions that are drawn from them.
Sources of funding: Indicate the fundind source if any.

• Keywords should not be included in any of the sections of the abstract text, and written only in the section dedicated for keywords. Minimum 1 and maximum 6 keywords can be provided. All keywords should be written in lower case.

Presentation type:
  Abstracts will be considered either for:

• Oral Presentation
• Poster Presentation

ESCV 2024 Abstract Topics

• Advancements in diagnostics & clinical cases
• Development of new antiviral strategies
• Diagnostic stewardship & Diagnostic test accuracy
• Gastrointestinal viruses & Neurovirology
• Hepatitis, HIV and other blood borne viruses
  
• Immune response and vaccines
• Pandemic prepardness and health services research
  
• (Re-) emerging viral infections and one health
  
• Respiratory viruses
• Viral infections in pregnancy
• Viromics and virus discovery
• Viruses, tumors and immunocompromised hosts
• General virology

Evaluation Process and Acceptance Letters

All abstracts will be scored by the Scientific Committee following which the draft programme will be drawn up. While scientific merit is the most important factor in evaluating an abstract, the Committee will also take into account other factors such as the topic, geographic representation etc.

The presenting author of the abstract must be registered for the conference by 17 June 2024.

Please do not submit multiple copies of the same abstract.

It will be possible to make changes to already submitted abstracts until 6 May 2024. It will not be possible to make changes after this deadline. Please contact Ms. Mojca Rodic (mrodic@kenes.com) from Conference Organising Secretariat to edit after submitting an abstract.

Please ensure that the presenting author e-mail address is entered correctly to enable the Conference Organising Secretariat to communicate with you regarding your abstract. All information regarding the acceptance, any required adjustments, and scheduling will be communicated via the e-mail address of the presenting author.

Thank you for submitting your work for consideration. We look forward to welcoming you at the ESCV 2024 Annual Conference in September!